VYNE Therapeutics (VYNE) Earnings Analysis

VYNE Therapeutics (VYNE) next reports earnings on 2026-08-13, consensus EPS -0.18 USD. Last quarter (2026-05-14) it beat with EPS -0.0838 USD vs -0.18 USD est (+53.4%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E -1.86.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does VYNE next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.18 USD
Revenue estimate0.00B

VYNE earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-14-0.0838 USD-0.18 USD+53.4%Beat
2026-03-12-0.28 USD-0.2 USD-40%Miss
2025-11-06-0.17 USD-0.19 USD+10.5%Beat
2025-08-14-0.13 USD-0.23 USD+43.5%Beat
2025-03-06-0.28 USD-0.31 USD+9.7%Beat
2024-11-07-0.29 USD-0.24 USD-20.8%Miss
2024-08-14-0.22 USD-0.19 USD-15.8%Miss

Beat rate: 4/7 (57%) over reported quarters with consensus data.

VYNE valuation and analyst view

Trailing P/E-1.86
Trailing EPS-0.50171 USD
Price / book1.56
Dividend yield42.34%
Market cap0.01B
Analyst consensusBuy (1 buy / 1 hold / 0 sell)

Related research pages

Frequently asked questions

When is VYNE Therapeutics (VYNE)'s next earnings date?

VYNE Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.18 USD and revenue estimate of 0.00B.

Did VYNE beat earnings last quarter?

In its 2026-05-14 report, VYNE posted EPS of -0.0838 USD versus a -0.18 USD estimate — a beat of 53.4%.

What is VYNE's earnings track record?

Over the last 7 reported quarters with consensus data, VYNE beat estimates 4 times (57%).

What is VYNE's current P/E ratio and EPS?

VYNE trades at a trailing P/E of -1.86 on trailing EPS of -0.5017068836513281 USD.

What do analysts rate VYNE?

Analyst consensus is "Buy" across 2 ratings (0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell).